"Situé à la confluence du Val-de-Marne et de l'Essonne , le Centre Hospitalier Intercommunal de Villeneuve-Saint-Georges (CHIV) Lucie & Raymond Aubrac est un établissement de recours et de proximité sur un territoire de près de 400 000 habitants, alliant une expertise forte autour de prises en charge reconnues sur plusieurs secteurs. Il dispose de 565 lits et places et emploie plus de 2000 personnes. Il est organiséen 6 pôles d'activité : le pôle anesthésie et réanimation, le pôle chirurgie, le pôle femme-enfant, le pôle médecine, le pôle médico-technique et le pôle de santé mentale."

During the past decade, CHI Villeneuve-Saint-Georges conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHI Villeneuve-Saint-Georges" #1 sponsor was "ANRS, Emerging Infectious Diseases" with 8 trials, followed by "Centre Hospitalier Intercommunal Creteil" with 8 trials sponsored, "Biotronik France" with 2 trials sponsored, "Intergroupe Francophone de Cancerologie Thoracique" with 2 trials sponsored and "Ferring Pharmaceuticals" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHI Villeneuve-Saint-Georges" #1 collaborator was "ADECHOTECH" with 1 trials as a collaborator, "Allies in Cardiovascular Trials Initiatives and Organized" with 1 trials as a collaborator, "Association Nationale des Hépato-Gastroentérologues des Hôpitaux Généraux" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Bicetre Hospital" with 1 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "CHI Villeneuve-Saint-Georges" are "HIV Infections" (3 trials), "Acute Coronary Syndrome" (1 trials), "Advanced Non Small Cell Lung Cancer" (1 trials), "Asthma in Children" (1 trials) and "Atrial Fibrillation" (1 trials). Many other conditions were trialed in "CHI Villeneuve-Saint-Georges" in a lesser frequency.

Most popular intervention types in "CHI Villeneuve-Saint-Georges" are "Other" (8 trials), "Drug" (6 trials), "Behavioral" (1 trials), "Device" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Amikacin" (1 trials), "Analytical Treatment Interruption (ATI)" (1 trials), "Antiretroviral" (1 trials), "Blood draw" (1 trials) and "Budesonide Formoterol Drug Combination" (1 trials). Other intervention names were less common.

The vast majority of trials in "CHI Villeneuve-Saint-Georges" are 20 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "CHI Villeneuve-Saint-Georges". 1 are not yet recruiting, 4 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in CHI Villeneuve-Saint-Georges, 1 suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in CHI Villeneuve-Saint-Georges, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 6 trials that are defined as “Not Applicable".